RESEARCH
ONGOING CLINICAL TRIALS
/ SECOND-LINE STUDIES
Medimmune D4190C00022
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma.

Population: Immunotherapy-naive subjects with unresectable HCC who have progressed on, are intolerant of, or refused sorafenib-based therapy.


Phase I ADP-0033-001 Second line
A PHASE I OPEN LABEL, CLINICAL TRIAL EVALUATING THE SAFETY AND ANTI-TUMOR ACTIVITY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR ALPHA-FETOPROTEIN (AFPC332T) IN HLA-A2 POSITIVE SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)